Leighl NB, Hellmann MD, Hui R, et al. KEYNOTE-001: 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab. J Clin Oncol. 35, 2017 (suppl; abstr 9011).
Adjuvant sorafenib na RFA verbetert prognose van HCC-patiënten
aug 2022 | Maag-darm-leveroncologie